Jim Cramer Says Novo Nordisk A/S (NVO) Is ‘Down So Much’
We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight
JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...
JPMorgan says Novo’s Ozempic, Rybelsus inclusion in price negotiations expected
After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price ...
London's FTSE 100 closes at record high; Novo Nordisk slides after U.S. lists its drugs for price talks
Spain — one of Europe's fastest growing economies, according to the OECD — is set to publish import and export figures on ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding its use
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
STAT6d
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
Business Insider13d
JPMorgan says Novo’s Ozempic, Rybelsus inclusion in price negotiations expected
After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations – including Novo Nordisk’s (NVO ...
NBC New York13d
London's FTSE 100 closes at record high; Novo Nordisk slides after U.S. lists its drugs for price talks
Novo Nordisk shares have pared some losses but ... over the company's blockbuster weight loss and diabetes drugs. JPMorgan analysts said they had previously forecast a 50% cut in prices for ...